ANI Pharmaceuticals, Inc.
ANIP
$82.72
-$0.05-0.06%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 923.71M | 883.37M | 826.88M | 747.40M | 674.07M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 923.71M | 883.37M | 826.88M | 747.40M | 674.07M |
| Cost of Revenue | 361.86M | 341.31M | 310.95M | 280.63M | 260.49M |
| Gross Profit | 561.85M | 542.06M | 515.94M | 466.77M | 413.58M |
| SG&A Expenses | 313.77M | 316.65M | 299.17M | 292.19M | 260.04M |
| Depreciation & Amortization | 89.45M | 91.42M | 91.40M | 84.52M | 75.94M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 816.77M | 801.04M | 757.57M | 711.22M | 641.10M |
| Operating Income | 106.93M | 82.33M | 69.31M | 36.18M | 32.97M |
| Income Before Tax | 116.03M | 95.79M | 50.55M | -14.75M | -27.56M |
| Income Tax Expenses | 23.88M | 17.45M | 9.98M | -4.54M | -6.51M |
| Earnings from Continuing Operations | 92.15 | 78.34 | 40.57 | -10.21 | -21.05 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 92.15M | 78.34M | 40.57M | -10.21M | -21.05M |
| EBIT | 106.93M | 82.33M | 69.31M | 36.18M | 32.97M |
| EBITDA | 196.38M | 173.75M | 160.71M | 120.70M | 108.90M |
| EPS Basic | 4.09 | 3.48 | 1.70 | -0.75 | -1.16 |
| Normalized Basic EPS | 2.73 | 1.99 | 1.49 | 0.47 | 0.34 |
| EPS Diluted | 3.94 | 3.35 | 1.63 | -0.77 | -1.18 |
| Normalized Diluted EPS | 2.63 | 1.91 | 1.45 | 0.45 | 0.34 |
| Average Basic Shares Outstanding | 81.51M | 80.20M | 78.96M | 78.29M | 77.78M |
| Average Diluted Shares Outstanding | 84.72M | 83.22M | 80.89M | 79.20M | 78.22M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 0.82% | 1.48% | 3.85% | -15.91% | -7.72% |